Specify a stock or a cryptocurrency in the search bar to get a summary
Lipidor Ab
LIPILipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. It has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was incorporated in 2009 and is based in Danderyd, Sweden. Address: Svärdvägen 13, Danderyd, Sweden, 182 33
Analytics
WallStreet Target Price
10.17 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LIPI
Dividend Analytics LIPI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LIPI
Stock Valuation LIPI
Financials LIPI
Results | 2019 | Dynamics |